RenalytixAI’s KidneyIntelX™ Demonstrates Effectiveness In Monitoring Therapeutic Response in kidney health for Adults with type 2 diabetes
July 1, 2021
Renalytix has announced new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and improvements in kidney health in adults with type 2 diabetes. The data from an international study of 1,100 individuals with diabetic kidney disease (DKD) in the CANagliflozin Cardiovascular Assessment Study (CANVAS), was presented at the American Diabetes Association 81st Scientific Sessions Virtual Meeting (June 25-29, 2021).
“Until now, primary care physicians have not had an optimal way to assess risk for kidney disease progression in their type 2 diabetes patients. KidneyIntelX provides early risk stratification which allows us to optimize and target patients in early stages of kidney disease with new medications such as SGLT2i, and moreover, these data support how KidneyIntelX can help monitor these patients and their response to treatment. It helps address an unmet need and gives the PCP a better call to action in the monitoring and effective pharmacy management of patients,” said Marina Basina, Clinical Professor of Medicine (Endocrinology) at Stanford University School of Medicine.
“The ability of KidneyIntelX to assess SGLT2 inhibitor response and improvements in kidney health through repeat testing is a significant step towards broader utilization of new therapeutic agents to significantly reduce the risk of kidney failure. This is another demonstration of the unique value of the KidneyIntelX bioprognostic solution to assist in early and effective care management of the 12 to 15 million adults in the United States with diabetes and chronic kidney disease,” said Michael J. Donovan, CMO at Renalytix.
These results will be further evaluated through a growing body of real-world evidence and clinical effectiveness data driven by the KidneyIntelX multi-institutional study network in over 6,000 patients. The network is assessing the ability of KidneyIntelX to 1) to appropriately risk stratify patients in early stage (stage 1, 2 and 3) kidney disease; 2) help guide the optimal medication regimen based on individualized risk assessment; and 3) monitor therapeutic response and kidney health using repeat testing over time. KidneyIntelX is being deployed to manage DKD populations beginning at primary care level in partnership with large health care systems including the University of Utah, the Mount Sinai Health System, Atrium Health, and Wake Forest Baptist Health.
“The CDC estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease,” said Kelvyn Cullimore, president and CEO of BioUtah. “Renalytix is making great strides to offer providers better tools to optimize the care of patients with kidney disease.”